Panagene Inc. products

Mutations of IDH1 (isocitrate dehydrogenase 1,IDH1) can be found in glioblastoma and myeloproliferative neoplasm. Detection of IDH1mutations can be a positive predictor of a prognosis and a molecular marker for glioblastoma patients. On the other hand, it is reported that IDH1 mutations correlate with poor prognosis in myeloproliferative neoplasm. PNAClamp™ IDH1 Mutation Detection Kit is a new member of somatic mutation detection kits utilizing PNA-mediated PCR Clamping technology, and can help patients choose the right medicine and monitor prognosis.

PANAMutyper™ EML4-ALK Screening Kit is the qualitative diagnostic test kit which is able to detect 16 different EML4-ALK fusion genes of tissue from non-small cell lung cancer (NSCLC) patients using peptide nucleic acid (PNA) probes in a real-time PCR system. The PANAMutyper™ EML4-ALK Screening Kit is intended as an aid for screening EML4-ALK fusion-positive NSCLC patients who would be sensitive for receiving ALK inhibitor therapy such as crizotinib.

BRAF mutation is found in several cancers including thyroid cancer, malignant melanoma, ovarian cancer, colorectal cancer. In case of thyroid cancer, there are over 40 different types of BRAF mutation. Of these mutations, the V600E mutation on exon 15, i.e. change of nucleotide from T to A in 1799th base that results in change from valine to glutamate in amino acids, is most important with over 90% of frequency. Especially, BRAF V600E mutation is detected with ca. 45% of frequency in papillary thyroid carcinoma and is considered a prognostic maker for thyroid cancer.